Investment Objective
Emkay Capital Builder is a multi-cap portfolio, that aims to identify companies with the potential to build wealth over an investment horizon of 3-5+ years.
The strategy considers top 600 companies (by market cap) as its universe and is guided by a well-defined portfolio construction discipline to filter stocks based on strict limits and a three-pronged investment process.
Three-Pronged Investment Process
Earnings Growth
E-Qual Risk Framework
Purchase Price Discipline
Investment Framework
Long Term Investing
- Low churn
- Be patient before & after investing
Conviction & Patience
Focus on absolute Returns and high emphasis on Purchase Price
Compounding is the Name of the Game
Winning sustainable wealth
Do your own Homework
Research backed & process oriented investments
Focused Portfolio
Allocation Discipline to avoid concentration risk
Avoid Mistakes
- Avoid unscrupulous promoters/ management
- Businesses getting irrelevant
- Highly leveraged companies
- Euphoric valuation
Investment Theme
Using a bottom-up stock-picking strategy, the  Emkay Capital Builder portfolio aims to consistently identify businesses offering robust growth prospects and intrinsic value at a reasonable price. We employ in-house tools like E-Qual (India’s first governance-dedicated stock-picking model) to mitigate risks related to management quality.
Sector Allocation
Emkay Capital Builder uses a multi-cap strategy with 20-25 stocks.
*As on 31st March 2022
The portfolio has had zero blowouts since inception which can largely be attributed to the intensive processes laid out in the E-Qual Risk module that make it nearly impossible for any evasive business to make its way into the fund.
TOP 5 HOLDINGS | |
---|---|
DIVI S LABORATORIES LTD | 10.8% |
ICICI BANK LTD. | 10.3% |
ZOMATO LIMITED | 9.9% |
HDFC Bank Ltd | 9.3% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 7.7% |
TOP 5 HOLDINGS | PERCENTAGE |
---|---|
ZOMATO LTD | 12.9% |
DIVI S LABORATORIES LTD | 12.8% |
ICICI BANK LTD | 9.9% |
HDFC BANK LTD | 9.4% |
SUN PHARMACEUTICAL INDUSTRIES LTD | 8.3% |
*As on 31st Dec 2024
Performance Update
*As on 31st March 2022
Name | Value |
---|---|
Emkay Capital Builder TWRR | 17.60 |
BSE 500 (TRI) | 16.10 |
Outperformance (TWRR v/s Benchmark) | 1.50 |
Note: The portfolio returns are TWRR returns.
*As on 31st March 2022
Fund Management Team
Sachin Shah
Executive Director and Fund Manager, Emkay Investment Managers Ltd.
Sachin is a seasoned fund manager with over two decades of experience in the Indian equity markets. By virtue of his extensive research, Sachin realised early-on the need for a framework in which companies with evasively tricky standing needed to be filtered out very objectively, leading to the development of E-Qual Risk, EIML’s proprietary module which helps us to evaluate and compare listed companies on various aspects of governance. Sachin shares his knowledge and insights through various media interactions across print and digital platforms.
Kashyap Javeri
Head of Research and Fund Manager, Emkay Investment Managers Ltd.
Kashyap Javeri is a Fund Manager with more than a decade of experience in company and sector research. He brings exceptional insights into stocks and economy. Prior to joining Emkay Investment Managers, he was a rated BFSI analyst in Emkay Institutional Equities for eight years, and also worked with Sharekhan Ltd. as a midcap analyst. Kashyap brings with him immense in-depth knowledge not only in a variety of manufacturing and services sectors, but also in banking and economics.